J&J raises 2026 outlook as oncology products power Q1 beat
Source: SeekingAlpha
2026-04-14 06:50:44 ET
More on Johnson & Johnson
- Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally?
- Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030
- Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach
- Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M
- Johnson & Johnson Q1 preview: What to expect
Read the full article on Seeking Alpha
For further details see:
J&J raises 2026 outlook as oncology products power Q1 beat
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND
LGND Trading
0.77% G/L:
$287.03 Last:
39,079 Volume:
$287.41 Open:
LGND Latest News
June 23, 2026 04:00:00 am
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
June 22, 2026 07:00:00 am
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
June 14, 2026 07:20:01 am
Ligand Pharmaceuticals Director Unloads 2,501 Shares - Should You Be Concerned?
$3,626,553,727
18,304,000
0.22%
151
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
